Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia: Long-term effects of fludarabine and alemtuzumab treatment

Leukemia and Lymphoma

Volumn 47, Issue 7, 2006, Pages 1229-1238

  Kiaii, Shahryar ^a   Choudhury, Aniruddha ^a   Mozaffari, Fariba ^a   Rezvany, Reza ^a   Lundin, Jeanette ^b   Mellstedt, Håkan ^b   Österborg, Anders ^b  

^a Cancer Center Karolinska   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alemtuzumab; Fludarabine; Signaling; T cell

Indexed keywords

ALEMTUZUMAB; CD3 ANTIGEN; FLUDARABINE; GAMMA INTERFERON; INTERLEUKIN 4; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE LCK; PROTEIN KINASE ZAP 70; T LYMPHOCYTE RECEPTOR;

ADULT; AGED; ARTICLE; B CELL LEUKEMIA; CELL ISOLATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DONOR; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; LONG TERM CARE; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LEUKEMIA, B-CELL; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TIME FACTORS; VIDARABINE;

EID: 33747654423     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600565503     Document Type: Article

References (38)

1. Kipps, T. (2000) Chronic lymphocytic leukemia Curr Opin Hematol, 7, pp. 223-234.
2. Walunas, T and Lenschow, D and Bakker, C and Linsley, P and Freeman, G and Green, J and (1994) CTLA-4 can function as a negative regulator of T cell activation Immunity, 1, pp. 405-413.
3. Grewal, I and Flavell, R. (1997) The CD40 ligand. At the center of the immune universe? Immunol Res, 16, pp. 59-70.
4. Mu, X and Kay, N and Gosland, M and Jennings, C. (1997) Analysis of blood T-cell cytokine expression in B-chronic lymphocytic leukaemia: evidence for increased levels of cytoplasmic IL-4 in resting and activated CD8 T cells Br J Haematol, 96, pp. 733-735.
5. Hill, S and Peters, S and Ayliffe, M and Merceica, J and Bansal, A. (1999) Reduced IL-4 and interferon-gamma (IFN-gamma) expression by CD4 T cells in patients with chronic lymphocytic leukaemia Clin Exp Immunol, 117, pp. 8-11.
6. Scrivener, S and Goddard, R and Kaminski, E and Prentice, A. (2003) Abnormal T-cell function in B-cell chronic lymphocytic leukaemia Leuk Lymphoma, 44, pp. 383-389.
7. Lundin, J and Kimby, E and Bergmann, L and Karakas, T and Mellstedt, H and Osterborg, A. (2001) Interleukin 4 therapy for patients with chronic lymphocytic leukaemia: A phase I/II study Br J Haematol, 112, pp. 155-160.
8. Rai, K and Peterson, B and Appelbaum, F and Kolitz, J and Elias, L and Shepherd, L and (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia N Engl J Med, 343, pp. 1750-1757.
9. Lundin, J and Österborg, A. (2004) Advances in the use of monoclonal antibodies in the therapy of chronic lymphocytic leukemia Semin Hematol, 41, pp. 234-245.
10. Österborg, A and Mellstedt, H and Keating, M. (2002) Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia Med Oncol, 19(Suppl), pp. S21-S26.
11. Keating, M and Flinn, I and Jain, V and Binet, J and Hillmen, P and Byrd, J and (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study Blood, 99, pp. 3554-3561.
12. Rossmann, E and Lundin, J and Lenkei, R and Mellstedt, H and Österborg, A. (2001) Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies Hematol J, 2, pp. 300-306.
13. Salisbury, J and Rapson, N and Codd, J and Rogers, M and Nethersell, A. (1994) Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas J Clin Pathol, 47, pp. 313-317.
14. Österborg, A and Werner, A and Halapi, E and Lundin, J and Harmenberg, U and Wigzell, H and (1997) Clonal CD8+ and CD52 - T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52) Eur J Haematol, 58, pp. 5-13.
15. Rawstron, A and Rollinson, S and Richards, S and Short, M and English, A and Morgan, G and (1999) The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment Br J Haematol, 107, pp. 148-153.
16. Lundin, J and Porwit-MacDonald, A and Rossmann, E and Karlsson, C and Edman, P and Rezvany, M and (2004) Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia Leukemia, 18, pp. 484-490.
17. Hertenstein, B and Wagner, B and Bunjes, D and Duncker, C and Raghavachar, A and Arnold, R and (1995) Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma Blood, 86, pp. 1487-1492.
18. Coles, A and Wing, M and Smith, S and Coraddu, F and Greer, S and Taylor, C and (1999) Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis Lancet, 354, pp. 1691-1695.
19. Bergmann, L. (1997) Present status of purine analogs in the therapy of chronic lymphocytic leukemias Leukemia, 11(Suppl 2), pp. S29-S34.
20. Fenchel, K and Bergmann, L and Wijermans, P and Engert, A and Pralle, H and Mitrou, P and (1995) Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas Leuk Lymphoma, 18, pp. 485-492.
21. Byrd, J and McGrail, L and Hospenthal, D and Howard, R and Dow, N and Diehl, L. (1999) Herpes virus infections occur frequently following treatment with fludarabine: Results of a prospective natural history study Br J Haematol, 105, pp. 445-447.
22. Takada, K and Danning, C and Kuroiwa, T and Schlimgen, R and Tassiulas, I and Davis, J, Jr and (2003) Lymphocyte depletion with fludarabine in patients with psoriatic arthritis: Clinical and immunological effects Ann Rheum Dis, 62, pp. 1112-1115.
23. Anaissie, E and Kontoyiannis, D and O'Brien, S and Kantarjian, H and Robertson, L and Lerner, S and (1998) Infections in patients with chronic lymphocytic leukemia treated with fludarabine Ann Intern Med, 129, pp. 559-566.
24. Cheson, B. (1995) Infectious and immunosuppressive complications of purine analog therapy J Clin Oncol, 13, pp. 2431-2448.
25. Cheson, B and Bennett, J and Grever, M and Kay, N and Keating, M and O'Brien, S and (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment Blood, 87, pp. 4990-4997.
26. Boyum, A. (1977) Separation of lymphocytes, lymphocyte subgroups and monocytes: A review Lymphology, 10, pp. 71-76.
27. Mozaffari, F and Hansson, L and Kiaii, S and Ju, X and Rossmann, E and Rabbani, H and (2004) Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage Br J Haematol, 124, pp. 315-324.
28. Rossmann, E and Lewin, N and Jeddi-Tehrani, M and Österborg, A and Mellstedt, H. (2002) Intracellular T cell cytokines in patients with B cell chronic lymphocytic leukaemia (B-CLL) Eur J Haematol, 68, pp. 299-306.
29. Rezvany, M and Jeddi-Tehrani, M and Rabbani, H and Ruden, U and Hammarstrom, L and Osterborg, A and (2000) Autologous T lymphocytes recognize the tumour-derived immunoglobulin VH-CDR3 region in patients with B-cell chronic lymphocytic leukaemia Br J Haematol, 111, pp. 230-238.
30. Österborg, A and Dyer, M and Bunjes, D and Pangalis, G and Bastion, Y and Catovsky, D and (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia J Clin Oncol, 15, pp. 1567-1574.
31. Wendtner, C and Ritgen, M and Schweighofer, C and Fingerle-Rowson, G and Campe, H and Jager, G and (2004) Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission - experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG) Leukemia, 18, pp. 1093-1101.
32. Caligaris-Cappio, F. (2003) Role of the microenvironment in chronic lymphocytic leukaemia Br J Haematol, 123, pp. 380-388.
33. Mellstedt, H and Choudhury, A. (2006) T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil Cancer Immunol Immunother, 55, pp. 210-220.
34. Kono, K and Salazar-Onfray, F and Petersson, M and Hansson, J and Masucci, G and Wasserman, K and (1996) Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity Eur J Immunol, 26, pp. 1308-1313.
35. Carbone, J and Ohm, D. (2002) Immune dysfunction in cancer patients Oncology (Huntingt), 16(Suppl 1), pp. 11-18.
36. Elgert, K and Alleva, D and Mullins, D. (1998) Tumor-induced immune dysfunction: The macrophage connection J Leukoc Biol, 64, pp. 275-290.
37. Thompson, J and Figlin, R and Sifri-Steele, C and Berenson, R and Frohlich, M. (2003) A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma Clin Cancer Res, 9, pp. 3562-3570.
38. Elflein, K and Rodriguez-Palmero, M and Kerkau, T and Hunig, T. (2003) Rapid recovery from T lymphopenia by CD28 superagonist therapy Blood, 102, pp. 1764-1770.